PTSD Treatment: New Drug Study by FAU Shows Promise
- Okay, hear's a draft article based on the provided text, aiming to meet all the specified requirements (VALUE, components, self-check).
- A novel opioid partial agonist, PPL-138, is demonstrating encouraging results in preclinical studies for the treatment of Post-Traumatic Stress Disorder (PTSD), particularly when coupled with alcohol use disorder...
- What: A new drug, PPL-138, shows promise in treating PTSD, anxiety, chronic pain, and alcohol use disorder in rats.
Okay, hear’s a draft article based on the provided text, aiming to meet all the specified requirements (VALUE, components, self-check). I’ve expanded on the information, added structure, and incorporated the requested elements. I’ve also included placeholder table data – this would ideally be populated wiht specific data from the studies if available.
Promising New Drug, PPL-138, Shows Potential for Treating PTSD and Co-occurring Alcohol Use Disorder
Table of Contents
A novel opioid partial agonist, PPL-138, is demonstrating encouraging results in preclinical studies for the treatment of Post-Traumatic Stress Disorder (PTSD), particularly when coupled with alcohol use disorder (AUD) and chronic pain. Research suggests the drug selectively targets the underlying anxiety ofen driving these co-occurring conditions.
Understanding the Complex Relationship Between PTSD, AUD, and Chronic Pain
Post-Traumatic Stress Disorder (PTSD) is a debilitating condition affecting millions. Approximately 12 million adults in the United States – 4% to 8% of the adult population – live with PTSD. The impact is even more pronounced within the military community,where up to 30% of personnel and veterans are affected. However, PTSD rarely exists in isolation. A significant overlap exists with other conditions, most notably alcohol Use Disorder (AUD) and chronic pain. In fact, a staggering 63% of veterans with PTSD also struggle with AUD and/or chronic pain.
This co-occurrence isn’t coincidental. These conditions frequently exacerbate one another, creating a vicious cycle that makes treatment exceptionally challenging. Individuals with AUD or chronic pain are more likely to develop PTSD, and vice versa. The current therapeutic landscape offers limited solutions, with many available medications providing insufficient relief or carrying significant side effects. This unmet need has driven the search for novel treatment strategies.
How PPL-138 Works: Targeting the Brain’s Stress and Addiction Systems
Researchers at Florida Atlantic University’s Charles E. Schmidt College of Medicine, in collaboration with the University of Oklahoma College of Pharmacy, have been investigating a new drug, PPL-138, as a potential breakthrough. PPL-138 is an opioid partial agonist, meaning it activates opioid receptors in the brain, but to a lesser degree than full agonists (like morphine). This partial activation can provide therapeutic benefits without the same level of risk for addiction or severe side effects.
The drug is designed to target specific opioid receptors involved in both stress response and addiction pathways. By modulating these pathways, PPL-138 aims to address the underlying neurobiological mechanisms driving PTSD, anxiety, pain, and alcohol misuse. Intellectual property rights for PPL-138 are held by Phoenix PharmaLabs, Inc.,who are actively progressing the drug through clinical trials.
Study Design and Key Findings
The research involved two complementary studies conducted on rats.
* Study 1 (University of Oklahoma): This study investigated the long-term effects of PPL-138 on PTSD-related symptoms in a model of chronic traumatic stress.
* Study 2 (FAU): This study explored the interplay between trauma, anxiety, and alcohol use. Rats were divided into groups to represent varying levels of trauma exposure and anxiety.
The results, published in the British Journal of Pharmacology, revealed several key findings:
* Reduced Anxiety-Like Behavior: PPL-138 significantly reduced anxiety-like behaviors in rats exhibiting PTSD-like symptoms.
* Pain Response Mitigation: The drug also demonstrated a reduction in pain responses in traumatized rats.
* Selective Alcohol Consumption Reduction: Critically, PPL-138 selectively reduced alcohol consumption only in rats that had developed PTSD-like symptoms and displayed trauma-related anxiety. It did not affect alcohol intake in rats that were resilient to stress or did not exhibit anxiety.
* Sex-Specific Effects: The drug demonstrated efficacy in both male and female rats, suggesting broad applicability.
– drjenniferchen
These findings are